Altimmune (ALT) Scheduled to Post Earnings on Thursday

Share on StockTwits

Altimmune (NYSE:ALT) is set to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Altimmune (NYSE:ALT) last announced its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). The company had revenue of $1.63 million for the quarter, compared to analyst estimates of $2.41 million.

Shares of ALT opened at $1.78 on Tuesday. The firm’s 50 day simple moving average is $1.96 and its 200 day simple moving average is $2.27. Altimmune has a 1-year low of $1.70 and a 1-year high of $5.94.

Separately, Roth Capital reaffirmed a “buy” rating on shares of Altimmune in a research note on Friday, July 19th.

About Altimmune

Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.

Recommended Story: Cost of Capital Explained

Earnings History for Altimmune (NYSE:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ted Baker’s  “Under Review” Rating Reaffirmed at Panmure Gordon
Ted Baker’s “Under Review” Rating Reaffirmed at Panmure Gordon
SSE  Receives Neutral Rating from UBS Group
SSE Receives Neutral Rating from UBS Group
RSA Insurance Group  Receives “Outperform” Rating from Royal Bank of Canada
RSA Insurance Group Receives “Outperform” Rating from Royal Bank of Canada
WPP  Price Target Lowered to GBX 1,100 at JPMorgan Chase & Co.
WPP Price Target Lowered to GBX 1,100 at JPMorgan Chase & Co.
FedoraCoin  Price Up 10.9% Over Last Week
FedoraCoin Price Up 10.9% Over Last Week
Alphacat Market Capitalization Tops $479,604.00
Alphacat Market Capitalization Tops $479,604.00


© 2006-2019 Ticker Report